Response to media comment

RNS Number : 1247F

Omega Diagnostics Group PLC

12 November 2020

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Response to media comment

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment on the AbC-19 Rapid Test and rejects the conclusions drawn on the performance of the test.

The fact remains that the Department of Health and Social Care (DHSC) is satisfied with the performance of the test, as is the UK-RTC. Public Health England conducted its own evaluation at the DHSC's request, and the DHSC will continue to deploy the test for use in surveillance studies . Accordingly, Omega does not believe the antibody testing opportunity through the UK-RTC has diminished.

Omega also welcomes the positive news on the progress of a viable vaccine and believes the need for COVID-19 antibody testing generally has not gone away and will continue for some considerable time.

Contacts: 

Omega Diagnostics Group PLC	Tel: [phone]
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

SPCBLLFFBFLBFBX